References
- Miller LK, Devi LA. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implations. Pharmacol Rev 2011;63:461-470. https://doi.org/10.1124/pr.110.003491
- Talwar R, Potluri VK. Cannabinoid 1 (CB1) receptor-pharmacology, role in pain and recent developments in emerging CB1 agonist. CNS Neurol Disord Drug Targets 2011;10:536-544. https://doi.org/10.2174/187152711796235005
- Basu S, Dittel BN. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 2011;51:26-38. https://doi.org/10.1007/s12026-011-8210-5
- Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonist and antagonists. Curr Med Chem 2010;17:1360-1381. https://doi.org/10.2174/092986710790980050
- Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005;312:875-883. https://doi.org/10.1124/jpet.104.077974
- Black SC. Cannabinoid receptor antagonists and obesity. Curr Opin Invest Drugs 2004;5:389-394.
- Serra G, Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Mental Health 2007;3:25-36. https://doi.org/10.1186/1745-0179-3-25
- Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density on cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001;103:9-15. https://doi.org/10.1016/S0306-4522(00)00552-2
- Horti AG, Van Laere K. Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain. Curr Pharm Des 2008;14:3363-3383. https://doi.org/10.2174/138161208786549380
- Evens N, Bormans GM. Non-invasive imaging of the type 2 cannabinoid receptor, focus on positron emission tomography. Curr Top Med Chem 2010;10:1527-1543. https://doi.org/10.2174/156802610793176819
- Donohue SR, Varnas K, Jia Z, Gulyas B, Pike VW, Halldin C. Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors. Bioorg Med Chem Lett 2009;19:6209-6212. https://doi.org/10.1016/j.bmcl.2009.08.092
-
Tsujikawa T, Zoghbi SS, Hong J, Donohue SR, Jenko KJ, Gladding RL, Halldin C, Pike VW, Innis RB, Fujita M. In vitro and in vivo evaluation of
$^{11}C-SD5025$ , a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. Neuroimage 2014;84:733-741. https://doi.org/10.1016/j.neuroimage.2013.09.043 - Donohue SR, Krushinski JH, Pike VW, Chernet E, Phebus L, Chesterfield AK, Felder CC, Halldin C, Schaus JM. Synthesis, EX Vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for In Vivo imaging. J Med Chem 2008;51:5833-5842. https://doi.org/10.1021/jm800416m
-
Fan H, Ravert HT, Holt DP, Dannals RF, Horti AG. Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-[
$^{11}C$ ] methoxyphenyl)-N-(piperidin-1-yl-1H-pyrazole-3-carboxamide ([$^{11}C$ ]JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-[$^{11}C$ ]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([$^{11}C$ ]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor. J Labelled Compd Radiopharm 2006;49:1021-1036. https://doi.org/10.1002/jlcr.1125 -
Horti AG, Fan H, Kuwabara H, Hiltor J, Ravert HT, Holt DP, Alexander M, Kumar A, Rahmim A, Scheffel U, Wong DF, Dannals RF.
$^{11}C$ -JHU75528: A radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 2006;47:1689-1696. -
Liu P, Lin LS, Hamill TG, Jewell JP, Lanza TJ, Gibson RE, Krause SM, Ryan C, Eng W, Sanabria S, Tong X, Wang J, Levorse DA, Owens KA, Fong TM, Shen CP, Lao J, Kumar S, Yin W, Payack JF, Springfield SA, Hargreaves R, Burns HD, Goulet MT, Kagmann WK. Discovery of N-{(1S,2S)-2-(3-cyanophenyl)-3-[4-(2-[
$^{18}F$ ]fluoroethoxy) phenyl]-2-methylpropyl}-2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use. J Med Chem 2007;50:3427-3430. https://doi.org/10.1021/jm070131b -
Terry GE, Hirvonen J, Liow JS, Zoghbi SS, Gladding R, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Donohue SR, Pike VW, Halldin C, Innis RB. Imaging and quantification of cannabinoid CB1 receptors in human and monkey brains using
$^{18}F$ -Labeled inverse agonist radioligands. J Nucl Med 2010;51:112-120. https://doi.org/10.2967/jnumed.109.067074 -
Gao Y, Ravert HT, Dannals RF, Horti, AG. 5-(4-(2-[
$^{18}F$ ] fluoroethoxy)phenyl-1-(2,4-dichlorophenyl)-4-cyano-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([$^{18}F$ ]JHU88868), a novel radioligand for PET imaging of cannabinoid type 1 receptors. Curr Radiopharmaceuticals 2009;2:195-198. https://doi.org/10.2174/1874471010902030195 - Scott PJH. Methods for the incorporation of carbon-11 to generate radio-pharmaceuticals for PET imaging. Angew Chem Int Ed 2009;48:6001-6004. https://doi.org/10.1002/anie.200901481
-
Shao X, Schnau PL, Fawaz MV, Scott PJH. Enhanced radiosyntheses of [
$^{11}C$ ]raclopride and [$^{11}C$ ]DASB using ethanolic loop chemistry. Nucl Med Biol 2013;40:109-116. https://doi.org/10.1016/j.nucmedbio.2012.09.008 -
Shao X, Kilbourn MR. A simple modification of GE Tracerlab FX C Pro for preparation of [
$^{11}C$ ]carfentanil and [$^{11}C$ ]raclopride. Appl Radiat Isot 2009;67:602-605. https://doi.org/10.1016/j.apradiso.2008.12.013 - Shao X, Fawaz MV, Jang KS, Scott PJH. Ethanolic carbon-11 chemistry: The introduction of green radiochemistry. Appl Radiat Isot 2014;89:125-129. https://doi.org/10.1016/j.apradiso.2014.01.033
- ICH Harmonised Tripartite Guideline Impurities: Guideline for Residual Solvents Q3C(R5). 2011:1-29.
-
Gao M, Wang M, Zheng QH. A new high-yield synthetic route to PET CB1 radioligands [
$^{11}C$ ]OMAR and its analogs. Bioorg Med Chem Lett 2012;22:3704-3709. https://doi.org/10.1016/j.bmcl.2012.04.030